Edition:
United Kingdom

Grifols SA (GRLSbn.MC)

GRLSbn.MC on Madrid SE C.A.T.S.

17.60EUR
4:35pm BST
Change (% chg)

€0.48 (+2.80%)
Prev Close
€17.12
Open
€17.28
Day's High
€17.80
Day's Low
€17.28
Volume
60,247
Avg. Vol
105,767
52-wk High
€21.30
52-wk Low
€16.36

Chart for

About

Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €15,167.80
Shares Outstanding(Mil.): 687.55
Dividend: 0.14
Yield (%): 1.29

Financials

  GRLSbn.MC Industry Sector
P/E (TTM): 29.70 30.92 33.69
EPS (TTM): 0.82 -- --
ROI: 5.94 14.76 14.30
ROE: 16.00 16.26 16.03

Spanish stocks - Factors to watch on Thursday

The following Spanish stocks may be affected by newspaper reports and other factors on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

11 Oct 2018

Healthcare firm Grifols S.A. wins U.S. antitrust nod to buy Biotest US Corp

WASHINGTON Global healthcare company, Grifols S.A. , which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

01 Aug 2018

Healthcare firm Grifols S.A. wins US antitrust nod to buy Biotest US Corp

WASHINGTON, Aug 1 Global healthcare company, Grifols S.A., which is based in Spain, has won U.S. antitrust approval to buy Biotest US Corp on condition that it sells certain assets, the Federal Trade Commission said on Wednesday.

01 Aug 2018

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Firday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

25 May 2018

BRIEF-Grifols Q1 EBITDA Down 2.8 Pct At 297 Mln Euros YoY

* Q1 EBITDA 297.4 MILLION EUROS VERSUS 306.0 MILLION EUROS YEAR AGO

03 May 2018

Earnings vs. Estimates